Date: 2015-09-15
Type of information: Grant
Company: UM Cure 2020 project including Curie Institute (France), Academisch Ziekenhuis Leiden (The Netherlands), Universiteit Leiden (The Netherlands), The University of Liverpool (UK), The University of Manchester (UK), Uniwersytet Jagiellonski (Poland), Karlsruher institut fuer technologie (Germany), Fundacao D. Anna Sommer Champalimaud E DR. Carlos Montez Champalimaud (Portugal), Melanoma Patient Network Europe (Sweden),Pamgene International (The Netherlands), Pep Therapy (France), Seeding Science (France)
Investors: European Commission’s Horizon 2020 programme
Amount: € 6 million
Funding type: grant
Planned used: The “UM Cure 2020” project, by increasing the knowledge in uveal melanoma metastases, is to identify and validate at the preclinical level novel therapeutic approaches for their treatment, up to the initiation of UM-dedicated clinical trials sponsored by academia, biotech or pharma companies.
Others: * On September 15, 2015, “UM Cure 2020” project, an European consortium focusing on the treatment of uveal
melanoma (UM) the have been awarded a European H2020 grant of € 6 million.
The Consortium, led by Dr. Sergio RomanRoman (Institut Curie, Paris), brings together the major experts of uveal
melanoma in both patient care and basic/translational/clinical research, and in particular several European Centres of Excellence in clinical Ocular Oncology, as well as the patient organisation Melanoma Patient Network Europe and the two biotech companies PamGene and PEP-Therapy with expertise in biomarkers and preclinical & early clinical development, respectively.
Therapeutic area: Cancer - Oncology - Rare diseases
